<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>AIMS/HYPOTHESIS: The aim of the study was to examine the impact of <z:chebi fb="0" ids="35664">statin</z:chebi> or omega-3-acid ethyl <z:chebi fb="21" ids="35701">esters</z:chebi> 90 (omega-3 EE90; omega-3-acid ethyl <z:chebi fb="21" ids="35701">esters</z:chebi> 90 refers to a mixture of ethyl <z:chebi fb="21" ids="35701">esters</z:chebi> of n-3 fatty acids) on estimated <z:e sem="disease" ids="C0007222" disease_type="Disease or Syndrome" abbrv="CVD">cardiovascular disease</z:e> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CVD</z:e>) risk in community-based people with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> but without known <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CVD</z:e> and not taking <z:chebi fb="23" ids="18059">lipid</z:chebi>-lowering therapy </plain></SENT>
<SENT sid="1" pm="."><plain>METHODS: A central computer randomised 800 patients in 59 UK general practices to <z:chebi fb="0" ids="39548">atorvastatin</z:chebi> (n = 401, 20 mg/day) or placebo (n = 399) and omega-3 EE90 (n = 397, 2 g/day) or placebo (n = 403) in a concealed factorial manner </plain></SENT>
<SENT sid="2" pm="."><plain>Participants with <z:chebi fb="1" ids="47774">LDL-cholesterol</z:chebi> &lt;2.6 mmol/l, triacylglycerol &lt;1.5 mmol/l and estimated 10-year <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CVD</z:e> risk &lt;20% were compared at 4 months </plain></SENT>
<SENT sid="3" pm="."><plain>RESULTS: Mean (SD) age was 63.5 (11.7) years, HbA(1c) 6.9 (1.1) % and known <z:mp ids='MP_0002055'>diabetes</z:mp> duration (median [interquartile range]) was 4 (2-8) years </plain></SENT>
<SENT sid="4" pm="."><plain>Fifty-seven per cent were men, 90% white and 74% had an estimated 10-year <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CVD</z:e> risk &gt;or=20% </plain></SENT>
<SENT sid="5" pm="."><plain>Of 732 patients with 4-month data, more allocated <z:chebi fb="0" ids="39548">atorvastatin</z:chebi> (n = 371) compared with placebo (n = 361) achieved <z:chebi fb="1" ids="47774">LDL-cholesterol</z:chebi> &lt;2.6 mmol/l (91% vs 24%, p &lt; 0.001) and had estimated 10-year <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CVD</z:e> risks &lt;20% (38% vs 26%, p &lt; 0.001) </plain></SENT>
<SENT sid="6" pm="."><plain>No differences were seen between those allocated omega-3 EE90 (n = 371) compared with placebo (n = 361) for participants achieving triacylglycerol &lt;1.5 mmol/l (65% vs 60%, p = 0.18) or estimated 10-year <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CVD</z:e> risks &lt;20% (34% vs 30%, p = 0.18) </plain></SENT>
<SENT sid="7" pm="."><plain>There were no side effects of note </plain></SENT>
<SENT sid="8" pm="."><plain>CONCLUSIONS/INTERPRETATION: Many community-based diabetic patients without known <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CVD</z:e> remain at high <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CVD</z:e> risk despite <z:chebi fb="0" ids="35664">statin</z:chebi> treatment and require additional risk-reduction strategies </plain></SENT>
<SENT sid="9" pm="."><plain>The impact of omega-3 EE90 on <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CVD</z:e> risk will remain uncertain until clinical endpoint trial results are available </plain></SENT>
<SENT sid="10" pm="."><plain>TRIAL REGISTRATION: ISRCT no. 76737502 </plain></SENT>
</text></document>